Ákos F. Pap
YOU?
Author Swipe
View article: Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD Open
Background VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extr…
View article: Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism
Benefit–Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism Open
http://ClinicalTrials.gov , identifiers: NCT00403767 (ROCKET-AF), NCT00440193 (EINSTEIN DVT), NCT00439777 (EINSTEIN PE), NCT00439725 (EINSTEIN Extension), and NCT02064439 (EINSTEIN CHOICE).
View article: Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design
Thromboembolic Events in the Hemodialysis Setting: Understanding Risk Profiles and Cumulative Incidences to Inform Clinical Trial Design Open
Background People with kidney failure have a high risk of cardiovascular morbidity/death, including thromboembolic events. Factor XIa inhibitors are a new class of anticoagulants in development that may offer antithrombotic benefits with a…
View article: Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE
Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE Open
Background Risks of recurrence and major bleeding with extended anticoagulation in Asian patients with venous thromboembolism (VTE) are similar to those in non-Asian patients but risks according to baseline risk factor profiles is not well…
View article: Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial Open
View article: Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score Open
Aims Deciding to stop or continue anticoagulation for venous thromboembolism (VTE) after initial treatment is challenging, as individual risks of recurrence and bleeding are heterogeneous. The present study aimed to develop and externally …
View article: Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods
Evaluation of the benefit of rivaroxaban on VOYAGER PAD primary composite of limb, heart and brain outcomes using the global rank and win ratio methods Open
Background/Introduction The VOYAGER PAD trial demonstrated that rivaroxaban 2.5 mg twice daily added to background antiplatelet therapy reduced a composite of irreversible harm events of the heart limb and brain versus placebo in patients …
View article: Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr Open
Anticoagulant treatment of pediatric cancer–associated venous thromboembolism (VTE) has not been prospectively evaluated. Management of anticoagulation for cancer-associated VTE is often challenged by drug interactions and treatment interr…
View article: Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study Open
A total of 371 participants including 174 (46.9%) women and 197 (53.0%) men were included in the present analysis. At 3 weeks, there was no difference between men and women in complete clot resolution: 39.6% and 40.2%, respectively. The ab…
View article: Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin Open
View article: Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)
Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT) Open
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebr…
View article: Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Open
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of rivaroxaban plus aspirin versus aspirin …
View article: Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE) Open
Anticoagulant treatment of pediatric central venous catheter–related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefi…
View article: Rivaroxaban in Peripheral Artery Disease after Revascularization
Rivaroxaban in Peripheral Artery Disease after Revascularization Open
In patients with peripheral artery disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute …
View article: Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial Open
View article: Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial Open
Aims Neladenoson bialanate is a partial adenosine A1 receptor agonist with demonstrated beneficial effects on cardiac function in animal models. We aimed to assess the dose–response effect of neladenoson bialanate on cardiac structure and …
View article: Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction
Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction Open
ClinicalTrials.gov Identifier: NCT03098979.
View article: Randomised Controlled Trial of Rivaroxaban Compared to Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children
Randomised Controlled Trial of Rivaroxaban Compared to Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children Open
View article: Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study Open
View article: Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Risk of recurrent venous thromboembolism according to baseline risk factor profiles Open
Key Points The risk of recurrence in patients with VTE provoked by minor transient or persistent risk factors is uncertain. The risk of recurrence with VTE provoked by minor transient or persistent risk factors is similar to that with unpr…
View article: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Open
Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspir…
View article: Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists Open
Summary The study aim was to identify predictive factors for major bleeding in patients receiving the novel oral factor Xa inhibitor rivaroxaban or enoxaparin-vitamin K antagonists (VKAs) for the treatment of acute symptomatic venous throm…
View article: Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the <scp>EINSTEIN PE</scp> Study
Treatment of Pulmonary Embolism With Rivaroxaban: Outcomes by Simplified Pulmonary Embolism Severity Index Score from a Post Hoc Analysis of the <span>EINSTEIN PE</span> Study Open
Objectives The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index ( PESI ) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evalu…
View article: Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the <scp>EINSTEIN DVT</scp> and <scp>EINSTEIN PE</scp> Studies
Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the <span>EINSTEIN DVT</span> and <span>EINSTEIN PE</span> Studies Open
Objectives In the EINSTEIN DVT and EINSTEIN PE studies, the majority of patients received heparins to bridge the period during venous thromboembolism ( VTE ) diagnosis confirmation and the start of the study. In contrast to vitamin K antag…